May 9th 2024
Explore how dequalinium chloride stands as a promising alternative to metronidazole in treating bacterial vaginosis, offering comparable efficacy, safety, and tolerability, as revealed by a recent noninferiority trial.
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
15th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 11, 2024
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
4th Annual International Congress on the Future of Women’s Health™
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Unveiling metabolic markers of Candida albicans infection
February 27th 2024Discover how metabolomics sheds light on potential biomarkers for early detection and treatment of Candida albicans-induced vulvovaginal candidiasis, offering crucial insights into the pathogenesis of this prevalent inflammatory condition.
Read More
Demystifying bacterial vaginosis: Understanding, treatment, and breaking stigmas
February 26th 2024Misunderstandings surrounding bacterial vaginosis can delay treatment, but advancements such as XACIATO offer effective solutions, emphasizing the importance of open communication and continued research for comprehensive women's health care.
Read More
Oteseconazole outperforms fluconazole in treating severe vulvovaginal candidiasis
January 31st 2024A phase 3 trial demonstrated that oteseconazole (VIVJOA; Mycovia Pharmaceuticals) capsules exhibit improved therapeutic and mycological cure rates to fluconazole for treating severe vulvovaginal candidiasis.
Read More
Discussing the link between bacterial vaginosis and vulvovaginal candidiasis
January 25th 2024Explore the relationship between bacterial vaginosis and vulvovaginal candidiasis as revealed by a recent study, uncovering mixed interactions, antibiotic implications, and the potential role of vaginal microbiota in shaping this complex association.
Read More
Pruritic rash in vulvovaginal area of 2-year-old girl
May 12th 2023Three months ago, a healthy 2-year-old girl presented with a mildly pruritic rash with erythematous plaques, some silvery white, in the vulvovaginal area. She had no vaginal discharge or other symptoms. The rash is now more widespread, and new lesions have recently appeared on her lower back and thighs. What's the diagnosis?
Read More
Cleveland Clinic reexamines syphilis testing strategies after rise in cases
February 6th 2023After observing an increase in the rate of syphilis cases, the Cleveland Clinic Ob/Gyn & Women’s Health Institute has partnered with the Center for Pediatric Infectious Diseases to evaluate the effectiveness of current testing strategies.
Read More
Bacterial vaginosis during pregnancy may heighten risk of preterm birth, pregnancy loss
November 21st 2022Bacterial vaginosis during pregnancy may lead to increased risks for preterm birth, preterm delivery, and spontaneous abortion, according to new research in the Archives of Gynecology and Obstetrics.
Read More
Daré Bioscience announced yesterday that it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to support its efforts related to the development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.
Read More
Efficacy of N. sativa-honey vs. clotrimazole for VVC
November 9th 2022A study published in the journal Evidence-Based Complementary and Alternative Medicine found that both Nigella sativa (N. sativa) (black seed and black cumin)-honey vaginal cream and the antifungal medication clotrimazole significantly improve the symptoms of vulvovaginal candidiasis (VVC).
Read More
Prevalence of Candida species with IUD placement
October 18th 2022Three months after copper intrauterine device (IUD) insertion, nearly 1/3 of women were diagnosed with vulvovaginal candidiasis, compared to nearly 25% of women who received a hormonal IUD, according to a prospective study published in the journal Cellular and Molecular Biology.
Read More